Dual Incretin Deal Benchmarks in Metabolic & Obesity

Median Upfront

$1.2B

Range: $660M - $1.8B

Total Deal Value

$5.9B

Range: $3.8B - $7.9B

Royalty Rate

17.4% - 30%

Tiered up to 35%

Dev Milestones

$839M

Range: $569M - $1.1B

Model Your Deal

Market Analysis

Dual Incretin therapies in metabolic & obesity have seen significant M&A and licensing activity in recent years. Based on analysis of 2,500+ verified transactions, the median upfront payment for a Phase 2 dual incretin asset in metabolic & obesity is $1.2B, with total deal values reaching $5.9B. Development milestones average $839M, while regulatory milestones contribute $1.0B.

The metabolic & obesity dual incretin landscape is characterized by extremely high competitive intensity driven by the GLP-1 revolution and massive obesity market opportunity. Oral formulations, dual/triple incretins, and muscle-sparing approaches command unprecedented deal valuations. The recommended deal structure allocates approximately 21% to upfront payments and 79% to milestones, reflecting the risk-reward profile at the Phase 2 stage.

Royalty rates for dual incretin metabolic & obesity deals range from 17.4% to 30% at the base tier, with tiered escalation reaching 21.4%-35% on blockbuster sales. Commercial milestones averaging $2.8B further reward successful market penetration.

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.

Unlock Everything — $299/mo Pro

7-day money-back guarantee · Cancel anytime

Customize these benchmarks for your asset

Adjust phase, modality, competitive position, and 10+ other parameters.

Open Calculator

Frequently Asked Questions

What is the typical upfront for a dual incretin metabolic & obesity licensing deal?

Based on our analysis, Phase 2 dual incretin licensing deals in metabolic & obesity average $1.2B in upfront payments, with a range of $660M to $1.8B depending on data quality, competitive positioning, and territorial scope.

What is the total deal value for dual incretin metabolic & obesity transactions?

The median total deal value for Phase 2 dual incretin assets in metabolic & obesity is $5.9B, ranging from $3.8B to $7.9B. This includes development milestones ($839M), regulatory milestones ($1.0B), and commercial milestones ($2.8B).

What royalty rates are standard for dual incretin deals in metabolic & obesity?

Base royalty rates for dual incretin metabolic & obesity transactions range from 17.4% to 30%, with tiered escalations reaching 21.4%-35% on peak sales. Rates are influenced by mechanism differentiation, competitive landscape, and territorial scope.

How are milestones structured in dual incretin metabolic & obesity deals?

Dual Incretin metabolic & obesity deals allocate approximately 79% of total deal value to milestones. Development milestones ($839M) make up the largest share, followed by commercial milestones ($2.8B) and regulatory milestones ($1.0B).

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.

Unlock Everything — $299/mo Pro

7-day money-back guarantee · Cancel anytime

Related Benchmarks

Small Molecule in Metabolic & Obesity

View

GLP-1 Agonist in Metabolic & Obesity

View

Ready to Calculate Your Deal Terms?

Get instant, customized benchmarks based on real market data from 600+ biopharma licensing deals.

Start Calculating